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COMMENTARY
Evolution of Cancer Prevention and Control
Program at The Arizona Cancer Center
Frank L Meyskens, Jr. *
The opportunity to review the rapid evolution and history
of our Cancer Prevention and Control (CPC) Program at
The Arizona Cancer Center (ACC) was an invitation and
challenge that could not be resisted.
This commentary is largely a Weltanschauung and con-
sequently personal interpretation of the history of the CPC
Program at ACC. It is a mixture of descriptions and reflec-
tions on the development of this CPC Program, which I hope
will be helpful to investigators who work in this area or who
plan to do so.
Before I describe the elements of success of the program
and the history leading to that success, let me focus on one
perplexity that persists in the field of cancer prevention and
control. Over the past decade, many of my colleagues who
are in a variety of scientific disciplines have shaken their
heads and questioned the involvement of "good scientists"
in this area of research. This mindset has been disconcert-
ing, and I continue to find it difficult to accept, especially
when our group ventures into new, challenging, and "less
traditional" aspects of this program.
Elements of Success
Several elements have been vital to the success of the CPC
Program at ACC.
Benign and Nonthreatening Academic Environment
For a new program to successfully proliferate and differen-
tiate without the formation of malignant or fatal teratogenic
elements, it is important that the atmosphere be supportive
or at least neutral. Since both the clinical and basic science
programs of ACC were also undergoing rapid growth from
1976 to 1987, little internal competition existed; collegial-
ity was generally superb, and the opportunity for synergistic
scientific interactions across disciplines was extensive. The
global encouragement and support of a well-disposed dean
and a scientifically oriented and open-minded cancer center
director have been essential components of an environment
conducive to the spawning of the CPC Program at ACC.
Fundamental Belief That All Problem Solving Represents
Science
Cancer prevention and control is not and may never be a
distinct discipline. Its proponents and opponents need to ac-
cept this fundamental fact if CPC programs are to evolve in
the multidisciplinary milieu of cancer centers and universi-
ties. On the other hand, sniping between those engaged in
the "hard" and "soft" sciences about the relative "value" or
"science" of each discipline creates a no-win situation for
those who are attempting to develop a CPC program. Can-
cer prevention and control, by its very nature, is interdis-
ciplinary. For successful evolution of a CPC program at a
cancer center, emphasis must be placed not on the funda-
mental differences between the hard and soft sciences, but
on their common ground—the approach to problem solving
via the scientific method.
Dedicated Faculty and Staff
The funding of our CPC Program has increased from
zero in 1980 to about $8 million in 1987. Several areas of
expertise have been essential to this progress.
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Biostatistical and clinical trials support. A biostatistician
who is committed to clinical trials and has a good under-
standing of epidemiology and, if possible, biology is essential
to any CPC program.
Clinical pharmacology expertise. Adequate performance
of clinical trials with normal subjects or near-normal pa-
tients who do not have cancer requires detailed understand-
ing of the pharmacology of intervention agents. Our program
at ACC has attracted investigators who have extensive ex-
perience with cytotoxic drugs and who are dedicated to the
complex challenge of chemoprevention pharmacology.
Involvement of biologists with diverse specialties. An un-
derstanding of the process of carcinogenesis requires input
from biologists in a broad range of fields. For example, in
the future, major contributions to the prevention of cancer
can be expected in such arenas as genetic risk assessment
and.intermediate markers of cancer risk.
Diet and nutrition perspective. Many prevention trials in-
volve dietary manipulation or require assessment of dietary
intake as a confounding variable. In addition, the different
viewpoints of epidemiologists and nutritionists about dietary
variables is often striking, and the overall quality of a CPC
program is enhanced by combination of the two approaches.
Input from behavioral scientists. The proper conduct and
evaluation of studies in such areas as smoking cessation, risk
assessment, rehabilitation, and continuing care require exten-
sive use of behavioral approaches. Additionally, in contrast
to most therapeutic trials, the execution of prevention studies
requires great attention to compliance and/or adherence.
Integration of efforts. To ensure that interactions among
all of the specialists are continuing, dedicated staff support
and strong program and administrative direction have been
essential.
Successful Extramural Grant Support
No new program can flourish unless extramural support
is garnered. Multiple sources of support must be diligently
sought federal, state, and private sources, including founda-
tions and pharmaceutical companies. The multidisciplinary
nature of research in cancer prevention and control makes
the preparation of grant applications a formidable task and
the external review process more complex and variable than
that for other fields of study. On the other hand, the funding
options are considerably more extensive than those for any
one discipline. Creative integration of the diverse mandates
of a CPC program and organization and synthesis of the in-
formation into a meaningful presentation is difficult, but this
is the key to success.
Recognition of CPC Program as Community,
Academic, and Scientific Partnership
In these early years, the CPC Program at ACC has been an
environmentally driven (sunshine and skin cancer) program
depending on both the academic milieu and the community
for its success. We were fortunate to start with the problem of
skin cancer, since the issue was familiar to the community.
Our mistakes were made in a supportive arena, and they
were interpreted by the community as "growing pains" rather
than as a fundamental town-gown problem. The importance
of appreciation for the interdependence of the academic
and community constituencies and the necessity for their
interaction to achieve the success of a CPC program should
not be underestimated.
History
The success of the program has been an evolutionary pro-
cess. In June 1977, I arrived at the University of Arizona
in Tucson. I was immediately struck by two factors about
my new professional setting; the practice of medical oncol-
ogy was enormously different from that in my only pre-
vious experience, and cutaneous malignant melanoma was
very common and not under active investigation by any of
my new colleagues. A review of the literature on malignant
melanoma quickly underscored two important issues: the in-
cidence of the malignancy was increasing rapidly, and except
for early diagnosis and surgery, there was no effective treat-
ment (Only recently has the broader oncology community
really appreciated the former observation.) This realization
prompted an interest in both the prevention and treatment of
the disease, which led to growth of the CPC Program in two
distinct directions, chemoprevention and cancer control.
In the scientific community at this time, there was a great
deal of interest in retinoids for two reasons. First, these com-
pounds inhibited carcinogenesis, and second, in certain sys-
tems, they were strong effectors of the differentiated phe-
notype. The second property was particularly noteworthy
for cells from murine melanoma and to a lesser extent for
cells from human melanoma. These observations prompted
development of a program project grant with the purpose
of achieving. an understanding of the function and role of
retinoids in oncology from the molecular to the clinical level.
Funding of this application in 1980 led to excellent local in-
teractions between basic scientists and clinicians, provided
an initial important identification for a new and different
area of research activity, and established a focus for future
development. Additionally, I was promptly identified as the
local guru of vitamins, which resulted in many crazy early
morning phone calls.
In about 1979, in a parallel effort, our group became
interested in the chemoprevention of cervical cancer. As we
wished to avoid the systemic side effects of retinoids, we
embarked on a long detour to demonstrate that retinoids
could be delivered locally to the cervix in a safe and efficient
manner. These studies were initially funded locally through
small grants and as a developmental project of our program
project In 1982, we successfully competed for a contract
to expand this work. On the basis of highly encouraging
responses, we then proposed a randomized phase HI trial
of local 0-fra/is-retinoic acid for cervical dysplasia and were
awarded a 4-year grant (1985-1989).
A second major new area emanating from the program
project was interest in the chemoprevention of nonmelanoma
skin cancer, hi our first recompetition for the grant, we
shifted the emphasis to include chemoprevention and focused
on a phase IE trial of patients at high risk for skin cancer.
Unfortunately, our spotlight was misdirected, and we were
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unsuccessful in the first recompetition. This experience was
salutary in that we learned several important lessons:
(a) Not everyone was enthusiastic about chemopreven-
tion.
(b) Not everyone was enthusiastic about retinoids.
(c) There was a wide gulf between the public health ap-
proach and the medical oncology approach. The pub-
lic health approach sought use of the highest dose that
had no toxic effects, whereas the aim of the medical
oncology approach was to ensure evidence of biolog-
ical responsiveness by using a dose sufficient to pro-
duce some toxic effects.
These lessons were learned and mulled over, the problems
were recognized, the questions were refrained, and recompe-
tition for the grant was successful. Furthermore, these newly
acquired perspectives allowed our group to develop a strong
application to conduct a randomized (retinol vs. placebo)
phase HI trial of subjects at low risk for nonmelanoma skin
cancer, and a 4-year renewal request was subsequently suc-
cessful as well.
Implementation of these three chemoprevention trials has
led us to a fuller appreciation of the difficulties encountered
in performing chemoprevention studies in a free-living pop-
ulation. The three major lessons we have learned from these
studies are important to the successful implementation of
similar trials.
First, prevention trials have a level of visibility consider-
ably higher than that of therapeutic clinical studies. Patience
is essential, and there must be a willingness to deal repeat-
edly with federal and state authorities, private institutions,
and regulatory bodies. In our first three trials and in subse-
quent trials, the actual entry of subjects began an average
of 12 months after the scheduled date. The reasons for such
delays are numerous, and they range from the ridiculous (pre-
vious occupant of off-site leased space refused to move out)
to the sublime (no side effects allowed in a prevention trial).
Second, recruitment of subjects was initially more diffi-
cult than we expected, and the best methods for recruitment
varied markedly for the three trials. The necessity for help
with accrual led to major interactions with our Biomedi-
cal Communications Department. Successful general recruit-
ment strategies for these three trials also were very different,
ranging from media advertisements to individual physician
contacts. We have learned some important things that are
seemingly obvious. For example: (a) the content and design
of an advertisement for subjects in a trial are critical and
crucial, and (b) the placement of an ad is critical because
communication is a very sophisticated and exact science. If
the ad appears next to a story about the trial, the phone rings
off the hook. If the ad is placed next to the X-rated movie
section, the phone remains silent
Third, careers in cancer control and prevention are not
made overnight The task of interesting trainees or junior
faculty in prevention research has been difficult Further-
more, because the trials are long, appropriate publication of
new methods and/or interim observations that do not com-
promise the trial are very important to maintain morale and
a sense of success.
In November 1983, at one of our periodic scientific re-
treats, our group made the conscious decision to develop a
multidisciplinary colon cancer prevention program project.
Essential features included two clinical chemoprevention tri-
als using measurement of intermediate markers of risk as
well as dietary and behavioral science cores with service
and research functions. These trials required many long,
but fruitful, discussions to achieve an interdisciplinary un-
derstanding and respect for colleagues from different dis-
ciplines, in addition to extensive interaction with the lay
community. A subsequent supplementary grant (Minority
Investigator grant) expanded activities to include research is-
sues related to Hispanics and colon cancer. A happy accident
that evolved from our community interactions was develop-
ment of a strong association with the Sun City retirement
community and the associated Boswell Hospital. This large
retirement community has been very responsive to the study,
and a large study focusing on long-term epidemiologic eval-
uation (Arizona Health Study) led by Thomas Moon has be-
gun. In the development of our community cancer prevention
program, we have established formal cancer prevention units
in Tucson, Sun City, central Phoenix, and Mesa. Interactions
between the CPC and clinical oncology programs have led
to establishment of nine satellites in the Arizona community
for epidemiology, prevention, and clinical trials research.
The other major area of the CPC Program evolved from
our concern about the prevention and early detection of skin
cancer in Arizona. An educational and outreach program was
jointly initiated in 1980 with Michael Schreiber of the Tuc-
son dermatologic community and was designated the Ari-
zona Sun Awareness Program (ASAP). Using a number of
strategies, this program has provided education regarding the
basic principles of prevention and early detection of skin
cancer to both lay and professional communities. This ef-
fort has been internationally recognized, and each week we
receive requests from around the world to help in starting
similar programs. The success of this program was impor-
tant and has led to a fine working relationship between ACC
and the broader medical and lay communities. Additionally,
ASAP established a good rapport with community dermatol-
ogists, a necessity for performance of chemoprevention trials
in patients at risk for skin cancer. We soon realized the im-
portance of documenting the incidence of nonmelanoma and
melanoma skin cancer within our geographic region, and the
epidemiology program at ACC has set up a site-specific tu-
mor registry in southern Arizona. For future cancer control
phase IV and V trials, establishment of a statewide tumor reg-
istry will be important, and this is a goal we hope to achieve
soon.
An important effort to refocus our prevention program
during the past year has been the integration of biologic and
molecular investigations into the chemoprevention arena.
Our goal is simple yet difficult to determine the biologic
basis of specific cancers and to intervene using chemopre-
vention strategies based on this acquired knowledge. An ul-
timate goal is to develop risk profiles for subjects at high
risk for cancer by using modern molecular and biochemical
techniques. Intervention with chemoprevention agents could
then be more rationally based on true individual risk rather
than population estimates. We have recently established a
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preventive oncology clinic to provide a centralized locus to
register subjects at high genetic or familial risk for selected
cancers. This resource will provide a focus for research ac-
tivities in clinical oncology, screening and early detection,
genetic epidemiology, and biologic studies.
demonstrates the feasibility and possibilities for effective re-
search in the community. The academic, research, lay, and
professional communities can now cooperate in the study,
prevention, and control of cancer.
Future Plans
We have many plans for the future. These include progres-
sion of current prevention studies to more advanced phases;
new chemoprevention initiatives, including phase II trials in
patients with Barrett's esophagus and oral leukoplakia; and
a multi-institutional phase HI trial of cutaneous malignant
melanoma. Extensive phase I and II testing of candidate
chemoprevention agents in normal subjects or patients with
preneoplastic lesions is also under way.
Conclusions
The best treatment of cancer is its prevention. The CPC
Program that has evolved at ACC over the past decade not
only provides service to the community, but also uses the
community as a laboratory to conduct cancer prevention in-
vestigations. Our research activities have increased public
awareness of cancer prevention in Arizona so that it will be
easier to recruit subjects for additional investigations involv-
ing other cancers. This community-based research program
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The National Cancer Institute
announces its new, free public
education booklet on diet and
cancer. It offers practical advice
on healthy eating and identifies
high-fiber and low-fat foods that
may help to reduce the risk of
cancer.
Call 1-800-4-CANCER and order
your copies of Diet, Nutrition
and Cancer Prevention: The
Good News.
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